H. Lee Moffitt Cancer Center and Research Institute

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, H. Lee Moffitt Cancer Center and Research Institute sits in the top decile of US sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count).

502 total trials 82 currently recruiting 280 completed early-phase tilt top decile by trial count

H. Lee Moffitt Cancer Center and Research Institute: 502 sponsored US clinical trials, 82 recruiting.

H. Lee Moffitt Cancer Center and Research Institute sponsors 502 registered US clinical trials on ClinicalTrials.gov, 82 of them currently recruiting, and 280 completed. 5 of these trials are in Phase 3-4 (later-stage) and 335 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.

Top-decile sponsor footprint

H. Lee Moffitt Cancer Center and Research Institute ranks in the top decile of sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 43/100

280 of 344 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

502 total, page 5 of 11

COMPLETED Phase 1

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

NCT04052334
COMPLETED

Mobile APP Utilization for Enhanced Post-Operative Nutritional Recovery

NCT04091165
COMPLETED Phase 1

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

NCT03381183
TERMINATED Phase 2

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

NCT03921073
COMPLETED NA

Developing and Testing a Spanish-Language Intervention to Reduce Cancer-Related Sleep Disturbance

NCT04101526
COMPLETED

Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas

NCT04055688
TERMINATED Early Phase 1

Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma

NCT03927274
COMPLETED Phase 1

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

NCT03719768
TERMINATED Phase 2

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

NCT03514017
COMPLETED Phase 2

Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma

NCT03834623
TERMINATED Phase 2

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

NCT03874325
TERMINATED Phase 1

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

NCT03760523
COMPLETED Early Phase 1

Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia

NCT03904199
COMPLETED Phase 1

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

NCT03605927
COMPLETED Phase 1

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

NCT03758781
COMPLETED Phase 1

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

NCT03807765
COMPLETED

Emotional Support Messages Following a Cancer Diagnosis

NCT03840109
COMPLETED NA

Development of a Mindfulness-Based Treatment for the Reduction of Alcohol Use and Smoking Cessation

NCT03734666
TERMINATED Phase 2

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

NCT03630809
COMPLETED Phase 2

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT03686488
TERMINATED Phase 1

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

NCT03663166
COMPLETED Phase 1

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

NCT03712943
COMPLETED Phase 2

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

NCT03575325
TERMINATED Phase 2

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

NCT03411031
COMPLETED NA

Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers

NCT03656133
COMPLETED NA

Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients

NCT03674138
TERMINATED Phase 2

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

NCT03630120
COMPLETED Early Phase 1

Applying mHealth to Tobacco-related Health Disparities

NCT03404596
COMPLETED Phase 1

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

NCT03501368
COMPLETED NA

Improving Sleep in BMT Survivors

NCT03537963
COMPLETED

Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES)

NCT03906110
COMPLETED Phase 1

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

NCT03426891
TERMINATED Phase 2

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

NCT03406715
COMPLETED Phase 1

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

NCT03332498
COMPLETED Phase 1

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

NCT03370276
COMPLETED Phase 2

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

NCT03290079
TERMINATED NA

Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer

NCT03137693
COMPLETED Phase 1

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

NCT03215810
COMPLETED Phase 1

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

NCT03177291
COMPLETED Phase 2

Facilitating Smoking Cessation With Reduced Nicotine Cigarettes

NCT02796391
COMPLETED Phase 1

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

NCT02780609
COMPLETED Phase 1

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

NCT03112590
COMPLETED NA

Patient Navigation in the Adolescent and Young Adult (AYA) Cancer Population

NCT03176576
COMPLETED Phase 1

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

NCT02891603
COMPLETED Phase 1

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

NCT03072043
COMPLETED NA

Screen to Save: NCI Colorectal Cancer Outreach & Screening Initiative

NCT05064410
COMPLETED

Refining and Testing the Electronic Social Network Assessment Program (eSNAP)

NCT03026699
COMPLETED Phase 1

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

NCT02779855
COMPLETED Phase 2

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

NCT02964078
COMPLETED

Biobank for African American Prostate Cancer Research in Florida

NCT03232411
← Previous Page 5 of 11 Next →

Phase Distribution

PhaseTrial count
Phase 1 167
Phase 2 168
Phase 3 3
Phase 4 2

Therapeutic Areas

Prostate Cancer 12
Pancreatic Cancer 11
Non-Small Cell Lung Cancer 11
Breast Cancer 10
HER2-positive Breast Cancer 7
Smoking Cessation 7
Lung Cancer 7
Leukemia 6
Acute Myeloid Leukemia 6
Triple Negative Breast Cancer 6

What is open in the H. Lee Moffitt Cancer Center and Research Institute pipeline

82 recruiting of 502 indexed (16% open); 280 completed (56%).

Phase mix: 5 late (III/IV) vs 335 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

H. Lee Moffitt Cancer Center and Research Institute: open-pipeline peers nationwide

Peers matched on 502 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 0%5%10%15%20% Total trials Recruiting share H. Lee Moffitt Cancer Center and Research InstituteNational Heart, Lung, and Blood Institute (NHLBI)Gilead SciencesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Boehringer IngelheimCase Western Reserve UniversityDrexel UniversityAtlantic Health SystemBioMarin Pharmaceutical
H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 502 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this H. Lee Moffitt Cancer Center and Research Institute page

502 registered trials is a research-attention snapshot, not an endorsement of H. Lee Moffitt Cancer Center and Research Institute or any single study.

  • 82 of H. Lee Moffitt Cancer Center and Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition H. Lee Moffitt Cancer Center and Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. H. Lee Moffitt Cancer Center and Research Institute pipeline card: 502 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.